retatrutide sign up clinical trial Retatrutide Phase 3 Trial for Obesity and Overweight Completes Primary Study Retatrutide Achieves Up to 30.3%
Description
Rates of severe nausea or vomiting were reported in 3 to 8 percent of GLP-1 users, but confirmed gastroparesis diagnoses requiring gastric emptying studies were extremely rare
Green B
I have watched friends and acquaintances who take GLP1 agonists and lose weight speak about weight in ways that make me uncomfortable
After holding drops under the tongue, users swallow whatever remains
Despite trying to focus on whole foods, fruits, and vegetables, my lack of craving for them was frustrating
